<DOC>
	<DOCNO>NCT01999777</DOCNO>
	<brief_summary>This study design evaluate efficacy , safety , tolerability USL261 compare intranasal ( IN ) placebo treatment intermittent bout increase seizure activity .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy USL261 Patients With Increased Bouts Seizure Activity EMU</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subject admit institution 's EMU seizure characterization presurgical evaluation , admission plan within 28 day Subject body weight ≥ 40 kg ≤ 125 kg ( inclusive ) Subject establish diagnosis partial generalize epilepsy Subject history status epilepticus 6 month prior Screening Subject progressive neurological disorder brain tumor , demyelinate disease , degenerative central nervous system ( CNS ) disease likely progress next 12 month Subject respiratory failure ( risk respiratory failure ) severe cardiorespiratory disease New York Heart Association Class III IV functional status , require supplemental oxygen Subject acute narrowangle glaucoma Subject receive chronic benzodiazepine treatment ( defined average ≥ 4 administration per week ) safely withdraw treatment within washout period prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizure cluster</keyword>
	<keyword>acute repetitive seizure</keyword>
	<keyword>rescue treatment</keyword>
</DOC>